Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity

Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of... Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 REVIEW ARTICLE Anti–Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity Dana Darwish, BS,* Ru-Ik Chee, MD,* Samir N. Patel, MD,† Karyn Jonas, MSN,* Susan Ostmo, MS,‡ J. Peter Campbell, MD, MPH,‡ Michael F. Chiang, MD,‡ and R.V. Paul Chan, MD, FACS* evidence emerge. Abstract: Diagnosis and management of pediatric retinal conditions Intravitreal anti‒vascular endothelial growth factor (anti- such as retinopathy of prematurity (ROP) have been evolving signifi - VEGF) agents such as bevacizumab, ranibizumab, aflibercept, cantly with the availability of new technology and treatments. New imag- and conbercept have been shown to be effective in retinal vascu- ing systems, telemedicine, tele-education, and anti‒vascular endothelial lar disorders. In adults, anti-VEGF therapy has revolutionized the growth factor (VEGF) intravitreal pharmacotherapy are all changing the management of conditions such as exudative age-related macular way we diagnose and deliver care to children with pediatric retinal dis- degeneration and diabetic retinopathy. The use of anti-VEGF in ease. Fluorescein angiography and optical coherence tomography have retinopathy of prematurity (ROP) or other pediatric retinal condi- the potential to improve our diagnosis and management of disease, and tions, however, is less well defined. with improvements http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Asia-Pacific Journal of Ophthalmology Wolters Kluwer Health

Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity

Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/anti-vascular-endothelial-growth-factor-and-the-evolving-management-Uvzx3LJIcf

References (79)

Publisher
Wolters Kluwer Health
ISSN
2162-0989
eISSN
2475-5028
DOI
10.22608/APO.201850
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 REVIEW ARTICLE Anti–Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity Dana Darwish, BS,* Ru-Ik Chee, MD,* Samir N. Patel, MD,† Karyn Jonas, MSN,* Susan Ostmo, MS,‡ J. Peter Campbell, MD, MPH,‡ Michael F. Chiang, MD,‡ and R.V. Paul Chan, MD, FACS* evidence emerge. Abstract: Diagnosis and management of pediatric retinal conditions Intravitreal anti‒vascular endothelial growth factor (anti- such as retinopathy of prematurity (ROP) have been evolving signifi - VEGF) agents such as bevacizumab, ranibizumab, aflibercept, cantly with the availability of new technology and treatments. New imag- and conbercept have been shown to be effective in retinal vascu- ing systems, telemedicine, tele-education, and anti‒vascular endothelial lar disorders. In adults, anti-VEGF therapy has revolutionized the growth factor (VEGF) intravitreal pharmacotherapy are all changing the management of conditions such as exudative age-related macular way we diagnose and deliver care to children with pediatric retinal dis- degeneration and diabetic retinopathy. The use of anti-VEGF in ease. Fluorescein angiography and optical coherence tomography have retinopathy of prematurity (ROP) or other pediatric retinal condi- the potential to improve our diagnosis and management of disease, and tions, however, is less well defined. with improvements

Journal

The Asia-Pacific Journal of Ophthalmology – Wolters Kluwer Health

Published: May 1, 2018

There are no references for this article.